Clinical Trial: Rituximab - National Multiple Sclerosis Society

Skip to navigation Skip to content

Clinical Trial: Rituximab

Share

Details
Type of MS: SPMS
Treatment mode of action: To affect immune function
Number of Subjects: 80
Medication: Rituximab
Location: MD
Contact Information
Joan Ohayon Rosalind Ebinger
301-496-0064
Joan_Ohayon@nih.gov

Funding:

:National Institute of Neurological Disorders and Stroke 

Description

Researchers at the National Institutes of Health in Bethesda, Maryland are looking to recruit 80 people with secondary-progressive Multiple Sclerosis (secondary-progressive MS) to evaluate the safety and effectiveness of rituximab.  

Share